We verified the possibility of collecting large amounts of peripheral blood stem cells (PBSCs) to support three courses of adjuvant high-dose dense chemotherapy (HDDC) with high-dose epirubicin, preceded by dexrazoxane, and high-dose paclitaxel, in patients with highrisk breast cancer (X9 positive nodes). The mobilizing regimen consisted of high-dose epirubicin 150 mg/m 2 , preceded by dexrazoxane 1000 mg/m 2 (day 1), given in combination with paclitaxel 175 mg/m 2 (day 2), plus filgrastim. Of the 25 patients enrolled, one went off study due to a severe hypersensitivity reaction to paclitaxel, another did not undergo leukapheresis due to fever persistent after hematological recovery, while in 23 patients an adequate number of PBSCs was collected by a single leukapheresis. The median number of CD34+, CD34+/CD33À, and CD34+/CD38À cells collected per patient was 17 Â 10 6 /kg, 13.4 Â 10 6 /kg, and 1.5 Â 10 6 / kg, respectively. Neutropenia was the only grade 4 toxicity and lasted a median of 3 days. High-dose epirubicin, preceded by dexrazoxane for the first time used in mobilizing regimen, and paclitaxel plus filgrastim are effective in releasing large amounts of PBSCs, which can then be safely employed to support multiple courses of HDDC. Bone Marrow Transplantation (2003) 32, 251-255. doi:10.1038/sj.bmt.1704125 Keywords: stem cell mobilization; breast cancer; dexrazoxane; epirubicin; paclitaxel; filgrastim The ideal mobilizing regimen for patients with cancer should be one that contains the most effective antitumor drugs, and that is able to produce a collection of an adequate amount of peripheral blood stem cells (PBSCs). Combination chemotherapy with epirubicin and paclitaxel is one of the most active regimens for patients with breast cancer.
Summary:
We verified the possibility of collecting large amounts of peripheral blood stem cells (PBSCs) to support three courses of adjuvant high-dose dense chemotherapy (HDDC) with high-dose epirubicin, preceded by dexrazoxane, and high-dose paclitaxel, in patients with highrisk breast cancer (X9 positive nodes). The mobilizing regimen consisted of high-dose epirubicin 150 mg/m 2 , preceded by dexrazoxane 1000 mg/m 2 (day 1), given in combination with paclitaxel 175 mg/m 2 (day 2), plus filgrastim. Of the 25 patients enrolled, one went off study due to a severe hypersensitivity reaction to paclitaxel, another did not undergo leukapheresis due to fever persistent after hematological recovery, while in 23 patients an adequate number of PBSCs was collected by a single leukapheresis. The median number of CD34+, CD34+/CD33À, and CD34+/CD38À cells collected per patient was 17 Â 10 6 /kg, 13.4 Â 10 6 /kg, and 1.5 Â 10 6 / kg, respectively. Neutropenia was the only grade 4 toxicity and lasted a median of 3 days. High-dose epirubicin, preceded by dexrazoxane for the first time used in mobilizing regimen, and paclitaxel plus filgrastim are effective in releasing large amounts of PBSCs, which can then be safely employed to support multiple courses of HDDC. Bone Marrow Transplantation (2003) 32, 251-255. doi:10.1038/sj.bmt.1704125 Keywords: stem cell mobilization; breast cancer; dexrazoxane; epirubicin; paclitaxel; filgrastim The ideal mobilizing regimen for patients with cancer should be one that contains the most effective antitumor drugs, and that is able to produce a collection of an adequate amount of peripheral blood stem cells (PBSCs). Combination chemotherapy with epirubicin and paclitaxel is one of the most active regimens for patients with breast cancer.
1 Standard-dose epirubicin/paclitaxel combination plus cytokines are effective in mobilizing PBSCs with induction of white blood cell (WBC) nadirs of brief duration without severe thrombocytopenia. [2] [3] [4] Moreover, either high-dose epirubicin or high-dose paclitaxel followed by filgrastim are able to mobilize PBSCs in patients with breast cancer. 5, 6 Cardiotoxicity was clearly documented by both clinical and laboratory cardiac evaluation, when high single doses of epirubicin were administered. 7 Dexrazoxane is a derivative of EDTA that has been shown to decrease significantly the incidence of cardiomyopathy in patients treated with anthracyclines. 8 Results of a randomized trial demonstrated that dexrazoxane protects against the development of cardiotoxicity when high single doses of epirubicin are used, without affecting antitumor activity. 7 No data are available regarding the use of dexrazoxane in combination with high-dose anthracyclines, with or without other agents, for PBSC mobilization.
There is preclinical and clinical evidence that doseintensive chemotherapy has a greater antitumor effect in patients with breast cancer.
9-14 A number of different strategies for intensifying dose with PBSC support have been described. [15] [16] [17] [18] [19] [20] [21] The Norton-Simon model predicts that multiple, rapidly recycled applications of chemotherapy (dose dense) are more likely to eradicate residual cancer cells than either single or multiple applications with long intervals between cycles. 22 High-dose dense is an evolution of the dose-dense concept with an enhanced dose of the delivered drugs.
In an attempt to improve overall results in high-risk breast cancer patients (X9 positive nodes), we designed a pilot study of high-dose dense chemotherapy (HDDC) consisting of three courses of high-dose epirubicin, preceded by dexrazoxane, and high-dose paclitaxel with PBSCs and filgrastim support, every 16-19 days. In this study, we defined a research protocol to verify the stem cell mobilizing ability and safety of a single course of high-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel, and followed by filgrastim. We then assessed the ability of the collected PBSCs to support hematopoietic recovery after each of three courses of HDDC.
Patients and methods

Patient selection
Eligible patients were 18-60 years of age, with stage II-IIIA breast cancer with nine or more positive axillary nodes. Staging procedures included complete blood count, renal and hepatic function tests, chest X-ray, bone scan, and liver ultrasound. Patients were required to have a resting left ventricular ejection fraction (LVEF) greater than 50%. The study was approved by the Institutional Ethical Committee and written informed consent was obtained from all patients. Toxicity was graded in accordance with the National Cancer Institute Common Toxicity Criteria version 2.0. 23 
Treatment plan
The induction phase consisted of one course of epirubicin 150 mg/m 2 (given as a 2-h infusion) preceded by dexrazoxane 1000 mg/m 2 (given as a 1-h infusion) on day 1, and paclitaxel 175 mg/m 2 (given as a 3-hour infusion) on day 2. At 24 h after the paclitaxel administration, filgrastim was given at a dose of 5 mg/kg/day subcutaneously until the day of leukapheresis. The HDDC regimen is presented in Figure 1 .
Cardiac evaluation
A prospective evaluation of cardiotoxic effects of the HDDC regimen in breast cancer patients was planned. The cardiac evaluation was performed at the following time points: before start of chemotherapy, 1 month after the last course of HDDC but before radiotherapy, 1 month after completion of the radiotherapy, and 1, 2, 3, 4, and 5 years after the last course of HDDC. The cardiac evaluation included a history and physical examination with special attention to signs and symptoms related to congestive heart failure (CHF). At all time points, the cardiac function was assessed by echocardiography with determination of LVEF and ECG.
Supportive care
Supportive measures during the administration of chemotherapy included an antiemetic regimen consisting of dexamethasone 8 mg intravenously and ondansetron 8 mg intravenously 30 min prior to the initiation of each chemotherapeutic drug. Orphenadrine 40 mg intravenously and cimetidine 300 mg intravenously were administered 30 min prior to the commencement of the paclitaxel infusion, moreover, the dose of dexamethasone administered before paclitaxel was 20 mg instead of 8 mg. Antibiotic prophylaxis consisted of ciprofloxacin 500 mg orally twice daily from day +6 until recovery of the WBC count (ANC 410 9 /l) or fever requiring the initiation of parenteral antibiotics. All patients were seen every day in the outpatient clinic from day +6 until recovery of the WBC count.
PBSC collection
PBSC collection was initiated when the absolute number of progenitor cells exceeded 20/ml of peripheral blood. A target number of X6 Â 10 6 CD34+ cells/kg of body weight was considered adequate to support three courses of HDDC. The PBSC harvest was performed using the Spectra COBE BCT, Apheresis System (Lakewood, CO, USA). A total blood volume of 6-10 l was processed per single leukapheresis through an appropriate central venous access catheter or by venous puncture for 3-4 h at a flow rate of 45-50 ml/min.
Statistical analysis
Descriptive statistics are presented as the median and range. The relation between different hematological parameters of the peripheral blood and leukapheresis products was estimated by the nonparametric Spearman rank correlation. Comparisons between groups of the analyzed parameters were performed using the Student's t-test. A P value of o0.05 was considered significant.
Results
Patient characteristics
From September 1998 to March 2001, 25 consecutive patients with high-risk stage II-IIIA breast cancer were enrolled. The median age was 50 years (range High-dose epirubicin preceded by dexrazoxane U De Giorgi et al
Mobilizing regimen toxicity
One patient had a severe hypersensitivity reaction to paclitaxel with edema and skin rash, then went off study, due to the presence of high-dose paclitaxel in each course of HDDC (Figure 1 ). Another patient developed a grade 1 allergic reaction to paclitaxel with transient skin rash, and then continued the HDDC treatment regularly. Three patients had neutropenic fever, and one, requiring hospital admission due to fever persistent after hematological recovery, did not proceed to leukapheresis. The median duration of grade 4 neutropenia was 3 days (range 0-5). No patient had grade 4 thrombocytopenia, while three patients had grade 3 thrombocytopenia lasting 1 day. No patient required platelet transfusions. Two patients presented grade 3 anaemia, and required packed red blood cell transfusions. One patient developed grade 2 vomiting, one had grade 2 diarrhea, and three developed grade 1 peripheral neurotoxicity. Mild to moderate muscle and bone pain, related to the filgrastim administration, was well controlled with acetaminophen.
Stem cell collection
Of 23 patients, 22 (96%) achieved the minimum threshold number of 6 Â 10 6 CD34+ cells/kg with a single leukapheresis. A collection slightly inferior to the threshold fixed was achieved in one patient (4.5 Â 10 6 CD34+ cells/kg), and then this patient regularly underwent HDDC. In all 23 patients, the CD34+ cells harvested with a single leukapheresis were considered adequate to support three courses of HDDC.
The median time for leukapheresis was 11 days (range 10-13); 16 of 23 (70%) patients underwent the leukapheresis procedure on day +11. Median WBC and circulating CD34+ counts on the day of collection were 13.3 Â 10 Table 2) .
The age of patients did not correlate with CD34+ cells per kg collected. We found a correlation between WBC count and the number of CD34+ cells in the peripheral blood (r ¼ 0.68) and in the leukapheresis component (r ¼ 0.56) (Figures 2 and 3) . The yield of CD34+ cells per kg collected was found to correlate with the circulating CD34+ cell count (r ¼ 0.84) (Figure 4 ).
Hematopoietic recovery following stem cell infusion
A total of 23 patients underwent leukapheresis procedure after mobilizing regimen and then were assessable for the ability of the collected PBSCs to support hematopoietic recovery after each of three courses of HDDC. Hematopoietic recovery data were available from all patients for a total of 65 courses, because three patients interrupted the treatment due to prolonged grade 3 peripheral neurotoxicity. The prospective evaluation of cardiotoxicity is ongoing; none of the patients developed clinically apparent CHF within the first year after treatment. The first two patients were treated as in-patients until hematopoietic recovery, while the others were allowed to return home and were followed up as outpatients for hematopoietic recovery (all patients were on ciprofloxacin prophylaxis). The collected PBSCs supported rapid hematopoietic reconstitution. A total of 23 patients underwent reinfusion of a median of 5.7 Â 10 6 CD34+ cells/kg (range 1.5-12.8) after each of HDDC courses. The median time from 
Discussion
In high-risk breast cancer patients, several adjuvant highdose chemotherapy regimens are currently investigated. 15, 16, 24 The use of high-dose epirubicin is increasing in this setting, but the reported dose-response relation is limited by the development of a dose-dependent chronic cardiomyopathy, and the cumulative dose limit may be reached earlier with a marked increase in drug dose. 7 To pay attention to the cardioprotection of these patients is mandatory, and the use of dexrazoxane may be of paramount importance. Dexrazoxane protects against the cardiotoxicity of anthracyclines, at least in part, through the chelation of intracellular iron, which may decrease anthracyclineinduced free radical generation. 8 Dexrazoxane has also been reported to inhibit the catalytic activity of topoisomerase II and to potentiate the efficacy of a number of antitumor agents. 25, 26 Recently, dexrazoxane has shown protection against anthracycline extravasation, but the precise mechanism was not defined. 27 The putative side effects of dexrazoxane, resulting from phase I trials, include leukopenia, thrombocytopenia, reversible liver function abnormalities, mild nausea and vomiting, and low-grade fever. 9, 26, 28 The influence of dexrazoxane in mobilizing chemotherapy regimens containing high-dose anthracyclines has not yet been investigated.
In a previous study from our institution, epirubicin 150 mg/m 2 followed by G-CSF was tested as mobilizing agent in patients with breast cancer in first-line metastatic (n ¼ 12), inflammatory or locally advanced disease (n ¼ 8), and adjuvant setting (n ¼ 9). 5 Patients were mobilized after the first course of chemotherapy (n ¼ 14), two courses (n ¼ 9), and three or more (n ¼ 6). In this group of chemonaı¨ve or not heavily pretreated patients, the median number of CD34+ cells collected per patient was 12.9 Â 10 6 /kg (range 3.9-48.1), and the mean number of leukapheresis procedures per patient was 1.870.3 (range 1-3).
Single agent paclitaxel given with filgrastim support is effective in mobilizing hematopoietic stem cells. 2-4 However, it is difficult to compare data from PBSC mobilization performed in these three studies, because of the lack of standardization of CD34+ cell quantification assays, the different doses of paclitaxel used in combination with epirubicin 90 mg/m 2 in these three studies (135, 175, and 200 mg/m 2 , respectively), the variable number of courses of chemotherapy before harvesting, and the different characteristics of the patients.
In the current study, all patients who received leukapheresis underwent one collection, and 22 of these 23 patients reached the target of more than 6 Â 10 6 CD34+ cells/kg. One patient reached 4.5 Â 10 6 CD34+ cells/kg, which was considered adequate to support three courses of HDDC. Moreover, her hematopoietic recovery after each HDDC course was in the same range as other patients. The median of 17 Â 10 6 CD34+ cells/kg collected per patient with a single leukapheresis was superior to the results of our previous study with epirubicin 150 mg/m 2 followed by G-CSF. 5 This is a retrospective, historical comparison of insufficient statistical significance. However, it is likely that more PBSCs can be collected by adding paclitaxel. The role of dexrazoxane as mobilization agent cannot be assessed in this study, but it is likely that its addition to High-dose epirubicin preceded by dexrazoxane U De Giorgi et al high-dose epirubicin, paclitaxel, and filgrastim does not have a negative effect on PBSC collection. Moreover, none of the patients developed clinically apparent CHF within the first year after treatment; therefore, the use of dexrazoxane may be considered justified in this trial.
In conclusion, our data suggest that high-dose epirubicin, preceded by dexrazoxane, and paclitaxel plus filgrastim are effective in mobilizing large numbers of PBSCs, which can then be safely employed to support multiple courses of HDDC.
